JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
129.09
+1.05 (+0.82%)
At close: 4:00PM EST

129.42 +0.33 (0.26%)
Pre-Market: 6:16AM EST

Stock chart is not supported by your current browser
Previous Close128.04
Open127.71
Bid129.40 x 800
Ask130.36 x 800
Day's Range127.46 - 129.52
52 Week Range118.62 - 148.99
Volume7,631,960
Avg. Volume9,721,241
Market Cap346.217B
Beta (3Y Monthly)0.62
PE Ratio (TTM)226.87
EPS (TTM)0.57
Earnings DateJan 22, 2019
Forward Dividend & Yield3.60 (2.81%)
Ex-Dividend Date2019-02-25
1y Target Est145.50
Trade prices are not sourced from all markets
  • TheStreet.com10 hours ago

    Apple, Johnson & Johnson Team Up for Healthcare Project Involving Apple Watch

    are collaborating on a study of a new heart health program that combines a Johnson & Johnson app with the Apple Watch to detect irregular heartbeat rhythms. The research study hopes to find out whether the app and Apple Watch can help with early detection and diagnosis of atrial fibrillation, which affects about 33 million people worldwide, according to the two companies. "Through Apple Watch, people have been able to learn more about their heart health, including discovering they have AFib.

  • The Wall Street Journal12 hours ago

    [$$] Johnson & Johnson to Use Apple Watch App for Heart-Health Study

    Johnson & Johnson said Thursday that it has joined with Apple Inc. on a research study that will test the Apple Watch’s ability to help detect early irregular heart conditions in certain people before something life-threatening happens. Janssen Pharmaceuticals Inc., which is a part of J&J’s family of research and development companies, will work on the study. The company will use its J&J-developed heart health monitoring app on the latest Apple Watch series.

  • Benzinga14 hours ago

    MediPharm Labs, Pure Global Cannabis, Weekend Unlimited, Plus Products, Trulieve Make Elevator Pitches

    Dozens of top cannabis companies presented at the Benzinga Cannabis Capital Conference, held Wednesday at the Eden Roc Miami Beach. The company moves the highest volume of oil in Canada — up to $10 million in extract in a month.

  • Zacks22 hours ago

    Banks Keep Stocks Moving Higher

    Banks Keep Stocks Moving Higher

  • J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
    Zacks22 hours ago

    J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect

    J&J's (JNJ) Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter.

  • MarketWatch23 hours ago

    Apple and Johnson & Johnson collaborating on heart research project

    Johnson & Johnson's Janssen Pharmaceuticals Inc. is collaborating on a multi-year research study with Apple Inc. to look at improving outcomes for patients with atrial fibrillation, the companies announced Thursday. The study will investigate whether a heart health app by Johnson & Johnson, combined with Apple Watch's irregular rhythm notifications and ECG app, can accelerate diagnosis and improve outcomes for people with atrial fibrillation. Atrial fibrillation is a condition that affects 33 million people worldwide and can lead to blood clots, stroke and heart failure. The study will be based in the U.S., the companies said, and subjects will be individuals 65 years or older. Shares of Apple were down 0.5% in premarket trade Thursday and have fallen 1.8% in the year to date through Wednesday. Shares of Johnson & Johnson have fallen 0.8%, while the S&P 500 has gained 4.4% and the Dow Jones Industrial Average has gained 3.8%.

  • Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention
    PR Newswire23 hours ago

    Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention

    NEW BRUNSWICK, N.J., Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with Apple Inc. to investigate whether a new heart health program using an app from Johnson & Johnson in combination with Apple Watch's irregular rhythm notifications and ECG app can accelerate the diagnosis and improve health outcomes of the 33 million people worldwide living with atrial fibrillation (AFib), a condition that can lead to stroke and other potentially devastating complications.

  • 3 Weight-Loss Stocks in Focus on Rising Obesity Fears
    Zacks23 hours ago

    3 Weight-Loss Stocks in Focus on Rising Obesity Fears

    Three companies with bright prospects as the U.S. weight-loss industry keeps up its battle against obesity.

  • Benzinga23 hours ago

    The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...

  • Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd.
    PR Newswireyesterday

    Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd.

    NEW BRUNSWICK, New Jersey, Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced the completion of the acquisition of Ci:z Holdings Co., Ltd. (4924.T) (the "Company") for a total purchase price of approximately ¥230 billion. The acquisition was completed through a series of transactions that included an all-cash tender offer to acquire publicly held shares of the Company for ¥5,900 per share.  Johnson & Johnson plans to acquire the remaining shares of the Company that were not tendered in the tender offer through a share consolidation under Japanese law during the first half of 2019 and take appropriate actions to delist the Company from the Tokyo Stock Exchange. The Company, which markets the DR.

  • Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd.
    PR Newswireyesterday

    Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd.

    NEW BRUNSWICK, N.J., Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced the completion of the acquisition of Ci:z Holdings Co., Ltd. (4924.T) (the "Company") for a total purchase price of approximately ¥230 billion. The acquisition was completed through a series of transactions that included an all-cash tender offer to acquire publicly held shares of the Company for ¥5,900 per share.  Johnson & Johnson plans to acquire the remaining shares of the Company that were not tendered in the tender offer through a share consolidation under Japanese law during the first half of 2019 and take appropriate actions to delist the Company from the Tokyo Stock Exchange. The Company, which markets the DR.

  • Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
    Zacks3 days ago

    Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $129.36, moving +0.84% from the previous trading session.

  • Benzinga3 days ago

    Cannabis Company Avicanna Eyes Canadian IPO

    Avicanna focuses on several product categories, including plant-derived cannabinoid pharmaceuticals, phytotherapeutics, dermacosmetics and extracts. In 2017, Avicanna became the first marijuana company to be accepted into Johnson & Johnson (NYSE: JNJ)'s JLABS @ Toronto, an incubation life science center. Last year, the company acquired controlling interests in Sativa Nativa and Santa Marta Golden Hemp, in which it has 70-percent and 60-percent stakes, respectively.

  • Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
    Zacks3 days ago

    Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?

    Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why Geron Stock Dropped 44% in 2018
    Motley Fool3 days ago

    Why Geron Stock Dropped 44% in 2018

    Johnson & Johnson's decision to hand back imetelstat's rights caused Geron's share price to crumble last year.

  • TheStreet.com3 days ago

    Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

    Have you ever watched a top five economy in terms of nominal GDP try to stay on it's feet as other "top fives" inflict harm not only upon each other, but upon themselves? You may recall that the export driven German economy had contracted q/q in Q3 2018. At growth of 1.5% for the year, the German economy grew at the slowest pace since 2013, but the implication, which is a far more significant takeaway would be that the engine behind Eurozone growth did not fall into recession in late 2018.

  • Markit3 days ago

    See what the IHS Markit Score report has to say about Johnson & Johnson.

    # Johnson & Johnson ### NYSE:JNJ View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for JNJ with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting JNJ. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $16.11 billion over the last one-month into ETFs that hold JNJ are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. JNJ credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Teva Pharmaceutical Industries Limited Stock a Bargain?
    Motley Fool4 days ago

    Is Teva Pharmaceutical Industries Limited Stock a Bargain?

    Teva's shares were unfairly punished last month.

  • Reuters4 days ago

    U.S. lawmaker launches investigation into pharma drug pricing

    A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Representative Elijah Cummings, who chairs the House Oversight Committee, sent letters to 12 drugmakers seeking information on price increases, investment in research and development, and corporate strategies to preserve market share and pricing power, his office said in a statement.

  • House Dems announce sweeping investigation of drug pricing
    Associated Press4 days ago

    House Dems announce sweeping investigation of drug pricing

    House Democrats announced a sweeping investigation Monday of the pharmaceutical industry's pricing practices, jockeying for the upper hand with the Trump administration on an issue that concerns Americans across the political spectrum. Oversight and Reform Committee Chairman Elijah Cummings said he's sent letters to 12 major drugmakers seeking detailed information and documents about pricing practices for brand-name drugs to treat diseases including cancer, diabetes, kidney failure and nerve pain. Cummings, a Maryland Democrat, said he wants to find out why prices have increased so dramatically for some existing medications, as well as how drug companies determine the prices of newly introduced medicines.

  • CNBC4 days ago

    House Democrats launch drug-pricing probe into a dozen major health-care companies

    AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.

  • A Look at Dow ETF Ahead of Q4 Earnings
    Zacks4 days ago

    A Look at Dow ETF Ahead of Q4 Earnings

    Let's delve into the Q4 earnings picture that will likely set up the movement of Dow Jones ETF in the coming days.

  • Stock Market Power Rankings: Amazon Back on Top
    Motley Fool5 days ago

    Stock Market Power Rankings: Amazon Back on Top

    They're big, beautiful, and ranked from 1 to 50.

  • Business Wire6 days ago

    ATTENTION JNJ EMPLOYEES: Zamansky LLC Investigates Possible ERISA Violations in the Johnson & Johnson Savings Plan

    Zamansky LLC investigates Johnson & Johnson Inc. (JNJ) (“J&J” or the “Company”) on behalf of its current and former employees for potential violations of the federal Employee Retirement Income Security Act (“ERISA”) in the J&J Savings Plan (the “Plan”). Zamansky LLC is a leading stock law firm with a practice in securities fraud, ERISA and employment class actions.

  • Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018
    Motley Fool6 days ago

    Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018

    A reversal of fortunes made last year one for the record books.